Amgen Inc. has announced groundbreaking results from its Center for Observational Research (CfOR), highlighting significant advancements in the use of real-world data $(RWD.AU)$ and real-world evidence (RWE) to revolutionize drug development and patient treatment. The recent study, published in JAMA, involved collaboration with leading academic and industry partners to enhance data quality by integrating structured and unstructured data from electronic health records, claims, and mortality data using artificial intelligence methods. This research, which analyzed data from over 120,000 U.S. asthma patients, demonstrated a substantial improvement in data quality, meeting the new FDA regulatory standards. These findings are expected to accelerate the design of representative clinical trials and, in some cases, even replace trial arms with RWE-based approaches, ultimately advancing Amgen's mission to deliver innovative medicines to patients and increase trust in the evidence process.